What is BioBDx?
BioBehavioral Diagnostics Company (BioBDx) is dedicated to the development, manufacturing, and marketing of proprietary diagnostic systems aimed at the quantitative assessment of behavioral disorders. Its flagship product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity Disorder (MMAT/ADHD System), is engineered to assist clinicians in making precise, office-based diagnoses for ADHD. This capability is crucial for ensuring that patients receive prompt and appropriate treatment, addressing a significant need in mental health diagnostics.
How much funding has BioBDx raised?
BioBDx has raised a total of $22.3M across 4 funding rounds:
Series A
$8.5M
Series B
$10M
Debt
$700K
Debt
$3.1M
Series A (2007): $8.5M with participation from Sevin Rosen Funds' companies and Tullis-Dickerson & Co.
Series B (2010): $10M led by Sevin Rosen Funds and Tullis Health Investors
Debt (2011): $700K, investors not publicly disclosed
Debt (2011): $3.1M, investors not publicly disclosed
Key Investors in BioBDx
Sevin Rosen Funds
Sevin Rosen Funds (SRF) is a Texas-based venture capital firm credited with pioneering the personal computing revolution in the 1980s and also venture investing in Dallas. It was established in 1981 by L. J. Sevin, a former Texas Instruments engineer, and Ben Rosen, and was one of the leading investors on the US West Coast.
Tullis Health Investors
Tullis Health Investors is a private equity firm that specializes in investing in high-growth, commercial-stage healthcare companies across various sectors including medical devices, healthcare services and technology, specialty pharmaceuticals, and biotechnology. The firm focuses on building long-term value through investments in people, products, technologies, and services that significantly impact global health.
What's next for BioBDx?
With a substantial enterprise-level funding history and a recent strategic investment, BioBDx is positioned for accelerated growth and market penetration. The company's focus on ADHD diagnostics, a condition affecting a significant population, provides a strong foundation for future expansion. Future endeavors will likely involve further refinement of the MMAT/ADHD System, potential development of diagnostics for other behavioral disorders, and broader commercialization efforts to reach a wider clinical audience. The strategic nature of the recent capital infusion suggests potential partnerships or market access initiatives that could significantly enhance BioBDx's trajectory.
See full BioBDx company page
